Progenitor Cell Therapy Expands Manufacturing Operations

The companys new cell therapy development and manufacturing facility in Allendale is being built to accommodate increasing client demand for clean-room and support space, according to the company.

The company-owned 30,000-square-foot facility will provide clients with access to multiple clean-room manufacturing suites, each with independent air-handling and laboratory systems, to support PCTs existing and future clients with projects ranging from process/product development to phase I-II-III clinical trial, fill/finish operations and commercial product manufacturing, according to PCT.

Progenitor Cell Therapy is proud of the work we have performed for clients over the past 11 years in what was our very first manufacturing facility in Hackensack, N.J., said PCT President Robert Preti. We are excited to now be moving operations into and serving our clients from our third location, a new state-of-art facility which will allow us to combine our multiple East Coast operations into one facility with increased capacity and significant room for continued expansion.

The development of the new facility is a multi-phase project, according to the company.

The first phase, now completed, provides for new headquarters for the companys operations and for the initial installation of the freezer farm.

Subsequent phases, already underway, will bring the companys processing, manufacturing and development capabilities online during the remainder of the year, according to the company.